title: Transient expression of M-CSF is important for osteoclast-like cell differentiation in a monocytic leukemia cell line.
abstract: Cells of U937, a human monocytic leukemia cell line, differentiate into macrophages by treatment with 12-o-tetradecanoylphorbol-13-acetate (TPA), whereas cells treated with 1 alpha, 25-dihydroxyvitamin D3 [1,25-(OH)2D3] continue to grow without undergoing differentiation. When U937 cells were successively treated with TPA and 1,25-(OH)2D3, tartrate-resistant acid phosphatase-positive multinucleated cells appeared at 5 days after the treatment. These osteoclast-like cells released a soluble form of 45Ca from 45Ca-labeled bone particles. These cells were not formed when the order of treatment with TPA and 1,25-(OH)2D3 was reversed. Use of either dexamethasone or interferon-gamma (IFN-gamma) was effective in inhibiting the formation of these osteoclast-like cells. The expression of c-src, c-fms, and macrophage colony stimulating factor (M-CSF) was induced by TPA treatment; however, TPA-induced M-CSF gene transcription was attenuated by the subsequent addition of 1,25-(OH)2D3. Furthermore, both dexamethasone and IFN-gamma impaired the attenuation of M-CSF expression, suggesting that the transient expression of M-CSF may be important for the formation of osteoclast-like cells.
authors.affiliation: Division of Cell Biology, Fujita Health University, Aichi, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Aoki
authors.forename: H
authors.initials: H
authors.lastname: Akiyama
authors.forename: H
authors.initials: H
authors.lastname: Hosoya
authors.forename: M
authors.initials: M
authors.lastname: Souda
authors.forename: T
authors.initials: T
authors.lastname: Morioku
authors.forename: T
authors.initials: T
authors.lastname: Marunouchi
mesh_terms: D000135:Acid Phosphatase / Q000494:pharmacology; D000818:Animals; D002116:Calcitonin / Q000494:pharmacology; D002117:Calcitriol / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002467:Cell Nucleus / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D004224:Diterpenes; D004357:Drug Synergism; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D016236:Genes, fms; D016391:Genes, src; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007527:Isoenzymes / Q000494:pharmacology; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D016173:Macrophage Colony-Stimulating Factor / Q000187:drug effects / Q000235:genetics*; D051379:Mice; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology*; D010641:Phenotype; D000071681:Tartrate-Resistant Acid Phosphatase; D013729:Terpenes / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D002273:Carcinogens; D004224:Diterpenes; D007527:Isoenzymes; D013729:Terpenes; C011309:mezerein; D003907:Dexamethasone; D016173:Macrophage Colony-Stimulating Factor; D007371:Interferon-gamma; D002116:Calcitonin; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D002117:Calcitriol; D013755:Tetradecanoylphorbol Acetate